Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March
Stealth BioTherapeutics Corp (Nasdaq: MITO) announced that CEO Reenie McCarthy will present at two virtual investor conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. ET, followed by Oppenheimer's 31st Annual Healthcare Conference on March 17 at 10:40 a.m. ET. Live audio webcasts will be available on Stealth's website, with replays archived for 30 days. Stealth focuses on therapies for diseases related to mitochondrial dysfunction, with significant product candidates including elamipretide and SBT-272.
- None.
- None.
BOSTON, March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Time: 7:00 a.m. ET
Oppenheimer's 31st Annual Healthcare Conference
Date: Wednesday, March 17, 2021
Time: 10:40 am ET
A live audio webcast of the presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcasts will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, such as POLG-related disorders, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march-301238949.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics present at the H.C. Wainwright Global Life Sciences Conference?
What is the date and time of Stealth BioTherapeutics' presentation at Oppenheimer's 31st Annual Healthcare Conference?
How can I listen to the Stealth BioTherapeutics investor presentations?
What is the focus of Stealth BioTherapeutics?
What product candidates is Stealth BioTherapeutics currently evaluating?
